Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).

@article{Parodi2010ComparisonOB,
  title={Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).},
  author={Guido Parodi and Angela Migliorini and Renato Valenti and Benedetta Bellandi and Umberto Signorini and Guia Moschi and Piergiovanni Buonamici and Giampaolo Cerisano and David Antoniucci},
  journal={The American journal of cardiology},
  year={2010},
  volume={105 8},
  pages={1053-9}
}
Previous studies have compared bivalirudin and unfractionated heparin (UFH) plus the routine use of glycoprotein IIb/IIIa inhibitors. They have demonstrated that bivalirudin can decrease bleeding complications without a significant increase in ischemic complications, resulting in a better net clinical outcome, as defined by the efficacy (ischemic… CONTINUE READING